---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-003129"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2024-05-28T23:59:59+00:00"
generated_at: "2026-06-01T08:08:11.470241+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics CEO Vered Bisker-Leib resigns; Thomas Schuetz appointed CEO

## Summary
- Vered Bisker-Leib, PhD, MBA resigned as CEO and board member effective May 28, 2024, not due to any disagreement.
- Thomas Schuetz, MD, PhD (President of R&D, Vice Chair) appointed President and CEO, and Principal Executive/Financial/Accounting Officer.
- Separation agreement: 18 months base salary, up to 18 months COBRA reimbursement, release of claims.
- Consulting agreement: 15 months at $45,000 annual fee; outstanding equity continues vesting during consultancy.
- Schuetz previously served as CEO; returns to role; Board of Directors reduced to seven members.

## SEC filing metadata
- accession: 0001171843-24-003129
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2024-05-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184324003129/0001171843-24-003129-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184324003129/f8k_052824.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-003129
- JSON: https://secwatch.observer/filing/0001171843-24-003129.json
- Plain text: https://secwatch.observer/filing/0001171843-24-003129.txt

## Key facts
- Executive change
  Thomas Schuetz was appointed as President and Chief Executive Officer at Compass Therapeutics, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: On May 28, 2024, the Board of Directors appointed Thomas Schuetz, MD, PhD, then-current President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, and as Principal Executive Officer, Principal Financial and Principal Accounting Officer of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1738021/000117184324003129/0001171843-24-003129-index.htm
- Executive change
  Vered Bisker-Leib resigned as Chief Executive Officer at Compass Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: On May 28, 2024, Vered Bisker-Leib, PhD, MBA, resigned as Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) and resigned as a member of the Board of Directors, of Compass Therapeutics, Inc. (the “Company”) effective the same date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1738021/000117184324003129/0001171843-24-003129-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.